Pernix Therapeutics Holdings (NASDAQ:PTX) stock had a bullish inflow of $0.02 million worth of trades on uptick and an outflow of $0 million in downticks on Wednesday. The total uptick to downtick ratio stood at 7.27. The net money flow into the stock was $0.02 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.01 million. $0.01 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Pernix Therapeutics Holdings (NASDAQ:PTX) stock traded down $0 , and reached $0.46, a drop of -0.97% over the previous day. On a weekly basis, the stock is -3.03%, over the previous weeks close.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc., Siegel Barry J, had purchased 5,000 shares in a transaction dated on August 19, 2015. The transaction was executed at $4.49 per share with total amount equaling $22,450. Currently the company Insiders own 5.62% of Pernix Therapeutics Holdings shares according to the proxy statements. Institutional Investors own 65.18% of Pernix Therapeutics Holdings shares.
The company shares have dropped -91.88% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $6.44 and the one year low was seen on May 24, 2016. The 50-Day Moving Average price is $0.48 and the 200 Day Moving Average price is recorded at $1.45. Pernix Therapeutics Holdings (NASDAQ:PTX): The stock opened at $0.47 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.47 for the day. The stock traded down to $0.45 during the day, due to lack of any buying support eventually closed down at $0.46 with a loss of -0.80% for the day. The stock had closed at $0.47 on the previous day. The total traded volume was 3,513,315 shares.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).